Can CV Monitoring Warnings Or REMS Restrictions Save Abbott's Meridia?
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency presents four regulatory options for the Endocrinologic and Metabolic Drugs Advisory Committee's Sept. 15 review of sibutramine's cardiovascular safety, ranging from continued marketing with no labeling changes to withdrawal.
You may also be interested in...
Meridia's CV Risks Not Distinguishable By Subgroups, FDA Cmte. Says
Eight of 16 members of Endocrinologic and Metabolic Drugs Advisory Committee vote to take Abbott's obesity drug off the market, saying no subgroup can be identified in which the cardiovascular risks could be managed through a Risk Evaluation and Mitigation Strategy.
Meridia's CV Risks Not Distinguishable By Subgroups, FDA Cmte. Says
Eight of 16 members of Endocrinologic and Metabolic Drugs Advisory Committee vote to take Abbott's obesity drug off the market, saying no subgroup can be identified in which the cardiovascular risks could be managed through a Risk Evaluation and Mitigation Strategy.
Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use
A matter of weeks away from the advisory committee review of the novel obesity drug lorcaserin, Arena's stock is flying high, yet the road to FDA approval, not to mention the daunting market, for obesity drugs looks more uncertain than ever